Share Name Share Symbol Market Type
AbbVie Inc NYSE:ABBV NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  -1.26 -1.41% 88.00 89.27 87.79 89.13 10,122,441 00:33:15

AbbVie: Skyrizi Met Endpoints in Phase 3 Plaque Psoriasis Study

14/01/2020 2:37pm

Dow Jones News

Historical Stock Chart

1 Month : From Dec 2019 to Jan 2020

Click Here for more AbbVie Charts.

By Michael Dabaie


AbbVie Inc. (ABBV) said Skyrizi met the primary and all ranked secondary endpoints, including superiority at week 52, versus Cosentyx in a head-to-head Phase 3 study in adults with moderate to severe plaque psoriasis.

Skyrizi showed significantly higher rates of skin clearance compared with Cosentyx, meeting the primary endpoint of superiority with at least a 90% improvement from baseline in the Psoriasis Area and Severity Index at week 52, AbbVie said.

AbbVie shares were up 1% to $87.64 premarket trade Tuesday.

The safety profile of Skyrizi was consistent with that observed in previously reported studies, with no new safety signals observed through week 52, the company said.

Skyrizi is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.


Write to Michael Dabaie at


(END) Dow Jones Newswires

January 14, 2020 09:22 ET (14:22 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

1 Year AbbVie Chart

1 Year AbbVie Chart

1 Month AbbVie Chart

1 Month AbbVie Chart
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200118 03:19:40